BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36045613)

  • 21. Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations.
    Barter ZE; Perrett HF; Yeo KR; Allorge D; Lennard MS; Rostami-Hodjegan A
    Biopharm Drug Dispos; 2010 Nov; 31(8-9):516-32. PubMed ID: 21104927
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Zhang JJ; Liu SB; Xue L; Ding XL; Zhang H; Miao LY
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4*1G and CYP3A metabolism.
    Collins JM; Wang D
    Pharmacogenet Genomics; 2022 Jan; 32(1):16-23. PubMed ID: 34320606
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcription factor binding to a putative double E-box motif represses CYP3A4 expression in human lung cells.
    Biggs JS; Wan J; Cutler NS; Hakkola J; Uusimäki P; Raunio H; Yost GS
    Mol Pharmacol; 2007 Sep; 72(3):514-25. PubMed ID: 17548528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.
    Gervasini G; Garcia M; Macias RM; Cubero JJ; Caravaca F; Benitez J
    Transpl Int; 2012 Apr; 25(4):471-80. PubMed ID: 22369694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.
    Monostory K; Tóth K; Kiss Á; Háfra E; Csikány N; Paulik J; Sárváry E; Kóbori L
    Br J Clin Pharmacol; 2015 Dec; 80(6):1429-37. PubMed ID: 26271661
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
    Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trans-eQTLs of the CYP3A4 and CYP3A5 associated with tacrolimus trough blood concentration in Chinese renal transplant patients.
    Lu H; Jiang H; Yang S; Li C; Li C; Shao R; Zhang P; Wang D; Liu Z; Qi H; Cai Y; Xu W; Bao X; Wang H; Li L
    Biomed Pharmacother; 2022 Jan; 145():112407. PubMed ID: 34781138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests.
    Lee SJ; Goldstein JA
    Pharmacogenomics; 2005 Jun; 6(4):357-71. PubMed ID: 16004554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing midazolam hydroxylation activity in human liver microsomes.
    He P; Court MH; Greenblatt DJ; von Moltke LL
    Drug Metab Dispos; 2006 Jul; 34(7):1198-207. PubMed ID: 16638818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients.
    Roy JN; Barama A; Poirier C; Vinet B; Roger M
    Pharmacogenet Genomics; 2006 Sep; 16(9):659-65. PubMed ID: 16906020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contrasting exome constancy and regulatory region variation in the gene encoding CYP3A4: an examination of the extent and potential implications.
    Creemer OJ; Ansari-Pour N; Ekong R; Tarekegn A; Plaster C; Bains RK; Itan Y; Bekele E; Bradman N
    Pharmacogenet Genomics; 2016 Jun; 26(6):255-70. PubMed ID: 27139836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.
    Gómez-Bravo MA; Apellaniz-Ruiz M; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Bilbao I; Alamo JM; Millán O; Brunet M; Rodríguez-Antona C
    Pharmacogenet Genomics; 2018 Feb; 28(2):41-48. PubMed ID: 29256966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
    Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
    Hesselink DA; Bouamar R; Elens L; van Schaik RH; van Gelder T
    Clin Pharmacokinet; 2014 Feb; 53(2):123-39. PubMed ID: 24249597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
    Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
    Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR genetic polymorphisms on tacrolimus metabolism in Chinese renal transplant recipients.
    Li CJ; Li L; Lin L; Jiang HX; Zhong ZY; Li WM; Zhang YJ; Zheng P; Tan XH; Zhou L
    PLoS One; 2014; 9(1):e86206. PubMed ID: 24465960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population.
    Hu YF; He J; Chen GL; Wang D; Liu ZQ; Zhang C; Duan LF; Zhou HH
    Clin Chim Acta; 2005 Mar; 353(1-2):187-92. PubMed ID: 15698606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.
    Li DY; Teng RC; Zhu HJ; Fang Y
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):466-74. PubMed ID: 23557867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA.
    Koch I; Weil R; Wolbold R; Brockmöller J; Hustert E; Burk O; Nuessler A; Neuhaus P; Eichelbaum M; Zanger U; Wojnowski L
    Drug Metab Dispos; 2002 Oct; 30(10):1108-14. PubMed ID: 12228187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.